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Abstract 
Uniformly adopted response criteria are essential for assessment of therapies 
incorporating conventional chemotherapy and chemoimmunotherapy regimens. 
Recently, immunomodulatory agents, such as immune checkpoint inhibitors, 
have demonstrated impressive activity in a broad range of lymphoma histologies.  
However, these agents may be associated with clinical and imaging findings 
during treatment suggestive of progressive disease (PD) despite evidence of 
clinical benefit (e.g., tumor flare or pseudo-progression).  Considering this finding 
as PD could lead to patients being prematurely removed from a treatment from 
which they actually stand to benefit. This phenomenon has been well described 
with checkpoint blockade therapy in solid tumors, and anecdotally seen in 
lymphoma as well.  To address this issue in the context of lymphoma 
immunomodulatory therapy, a workshop was convened to provide provisional 
recommendations to modify current response criteria in patients receiving these 
and future agents in clinical trials.  The term “Indeterminate Response” (IR) was 
introduced in order to identify such lesions until confirmed as flare/pseudo-
progression or true PD by either biopsy or subsequent imaging.  
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History of Response Criteria for Lymphoma with Conventional Therapy 
The first universally accepted response criteria for non-Hodgkin lymphoma (NHL) 
were published in 1999 by an International Working Group (IWG), and were also 
adopted for Hodgkin lymphoma (HL) (1).  These IWG guidelines defined 
complete remission (CR), partial remission (PR), complete remission 
unconfirmed (CRu), stable disease (SD), relapsed disease (RD) and progressive 
disease (PD), based on physical examination, chest x-ray, CT scan, single 
photon emission computed tomography (SPECT) gallium scans, and visual bone 
marrow evaluation.  The subsequent availability of positron emission tomography 
(PET), as well as immunohistochemistry and flow cytometry of the bone marrow 
resulted in the revised 2007 guidelines, including PET as a component of 
response assessment primarily for HL and diffuse large B-cell lymphoma 
(DLBCL)(2).   At the time, PET was recommended for post-treatment 
assessment of DLBCL and HL, but only in clinical trials for FL or other FDG avid 
histologies.   Further experience with the interpretation of PET scan results 
subsequently led to the Lugano Classification for staging and response 
assessment (3), incorporating PET-CT as a standard component of both the 
staging and response assessment of FDG-avid histologies, while retaining CT 
evaluation for other subtypes. 
 
Response Patterns with “Non-Conventional” Therapies 
As with prior criteria, the Lugano Classification was based on experience with 
traditional chemotherapeutic or chemoimmunotherapeutic regimens, primarily 
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incorporating rituximab.  However, the availability of an increasing number of 
biologic agents with immune mechanisms entering the clinic requires flexibility in 
interpretation of the recommendations to account for these agents’ biologic or 
immunomodulatory properties.  
 
Tumor flare was first formally described with immunomodulatory drugs (IMIDs), 
particularly lenalidomide, in patients with lymphomas and chronic lymphocytic 
leukemia (CLL) (4-7).  In about 15% of patients with CLL/small lymphocytic 
lymphoma (SLL), and less commonly in other lymphoma histologies, a “tumor 
flare” occurs, generally during the first two to three weeks of treatment.  This 
phenomenon is characterized by a rapid, often painful, self-limited, increase in 
the size of lymph nodes, and is often accompanied by fever, lymphocytosis, rash, 
and bone pain (8[Eva, 2010 #2551, 9).  The pathophysiology is speculated to be 
related in part to an immune phenomenon characterized by natural killer (NK)-
cell activation, modulation of co-stimulatory (CD80, CD83, CD86) surface 
molecules on CLL cells in vitro and in vivo, and an increase in levels of tumor 
necrosis factor (TNF)-α post-lenalidomide treatment, consistent with an acute 
inflammatory reaction (10).  Strict application of currently used CLL (11, 12) or 
lymphoma guidelines (3) to patients receiving IMIDs could result in incorrect 
assignment of PD, resulting in early cessation of therapy prior to achieving 
clinical benefit.  Other drugs with reported flare reactions include rituximab (13, 
14), which may also cause a paradoxical increase in IgM with an increase in 
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viscosity in patients with Waldenström macrglobulinemia (15, 16), and 
brentuximab vedotin (17). 
 
Another instance of atypical response pattern occurs with inhibitors of B-cell 
receptor signaling pathways.  Bruton tyrosine kinase (BTK) and 
phosphatidylinositol 3-kinase (PI3k) targeting agents are associated with major 
activity in CLL/SLL, mantle cell and other lymphomas, and are altering treatment 
paradigms (18, 19). In patients with CLL/SLL, and less often in other lymphomas, 
both idelalisib and ibrutinib may cause a rapid reduction in lymph node size and 
spleen mass, often with improvement of cytopenias, but associated with 
lymphocytosis (20-22).  This finding, which relates to a redistribution of 
lymphocytes from tissue sites to the peripheral blood (23, 24), may persist for a 
year or longer without signs or symptoms associated with disease progression 
and does not represent a suboptimal response to therapy. Rigorous application 
of the NCI-Working Group criteria of 1996 or the IWCLL of 2008 would result in 
the incorrect designation of PD in a significant number of patients, leading to 
premature discontinuation of drug despite other evidence of clinical improvement.  
Over time, many of these responses improve to partial or even complete 
responses as the lymphocytosis resolves.  This entity is now referred to as 
Partial Response with Lymphocytosis (25), which more accurately reflects the 
favorable nature of the response. Thus, the focus on traditional overall response 
rates is misleading and underestimates the magnitude of the clinical benefit of 
these agents. 
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Response Assessment with Immune Checkpoint Inhibitors 
The newest agents with which atypical responses are encountered are the 
immune checkpoint inhibitors.  These drugs counter the tumor’s usurpation of 
normal co-stimulatory or co-inhibitory immune regulatory pathways, thereby 
reactivating endogenous tumoricidal immune activity.  In solid tumors, anti- 
cytotoxic T-lymphocyte-associated (CTLA)-4 monoclonal antibodies (e.g., 
ipilimumab), and anti-programmed cell death (PD)-1 monoclonal antibodies (e.g., 
nivolumab, pembrolizumab) have achieved impressive results in patients with 
lung cancer, melanoma, renal cell carcinoma, and other tumor types (26-29).  
Nevertheless, response assessment may be confounded by a delayed effect of 
the drugs, allowing early tumor growth, or by therapeutic immune activation 
manifesting as an increase in the size of existing lesions or even the appearance 
of new lesions, so-called delayed response or pseudo-progression.  The 
recognition of these phenomena triggered efforts to formally characterize them 
and to modify standard response criteria to account for them (30).  For example, 
with ipilimumab monotherapy, four distinct response patterns have been 
reported: (a) shrinkage in baseline lesions, without new lesions; (b) durable 
stable disease (in some patients followed by a slow, steady decline in total tumor 
burden); (c) response after an increase in total tumor burden; and (d) response in 
the presence of new lesions. All patterns have been associated with survival that 
is similar to those with typical responses (31).  To account for these phenomena, 
Wolchok et al (31) proposed immune-related response criteria (IRC) that have 
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been incorporated into current trials of checkpoint blockade in patients with solid 
tumors (Table 1).  The core concepts of IRC are (30): 
1. Confirmation of progression via a subsequent scan to detect delayed 
responses (time point to be chosen based on characteristics of the 
disease under study); 
2. Measuring new lesions to include them into the total tumor volume; 
3. Accounting for durable stable disease as benefit; 
4. Treating beyond conventional progression if the clinical situation allows. 
 
Recently, Hodi et al (32) compared the predictability of overall survival and best 
overall response in a study of 655 patients with melanoma treated with 
pembrolizumab and showed that 5% had early pseudoprogression, whilst 3% 
experienced delayed pseudoprogression.  They concluded that, using Response 
Evaluation Criteria In Solid Tumor (RECIST), response would have been 
underestimated in 15% of patients, potentially resulting in premature termination 
of effective therapy. 
 
Checkpoint inhibitors have also demonstrated impressive activity in Hodgkin 
lymphoma (33) as well as activity across various other subtypes of NHL (34, 35).  
Not surprisingly, flare reactions or delayed responses similar to those in patients 
with solid tumors have been observed on those trials.  These atypical responses 
are characterized either by the early progression of existing lesions, later 
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followed by response, or by the development of new lesions, with or without 
tumor shrinkage elsewhere.   
 
At the present time, it is unclear how these reactions can be reliably identified 
and distinguished from true disease progression, as the breadth of experience 
accumulated in solid tumors is lacking in lymphoma.  To maximize both our 
understanding of these responses and the potential benefit of these therapies in 
patients with lymphoma, there is an urgent need for a framework to optimally 
categorize, report, and manage these atypical responses.  Such criteria are 
critical for treating physicians to optimally employ checkpoint inhibitor therapy, in 
order that effective therapy is not discontinued prematurely in patients 
experiencing benefit, as would occur using conventional response criteria.  In 
addition, it is important to gain experience in treating patients past the occurrence 
of conventional PD and to formally collect and analyze this information, in order 
to ascertain whether or not treatment past PD in formally defined circumstances 
can indeed provide a clinical benefit.   
 
The concepts that underlie the Immune Response Criteria (IRC) can also be 
applied to patient with lymphoma, and would clearly alter response assessment 
in some cases (Figures 1 and 2).  Yet simply applying the Immune Response 
Criteria (IRC) criteria derived from patients with solid tumors to lymphoma may 
not be adequate (Figures 1 and 2). Firstly, lymphoma response is currently 
assessed per the Lugano Classification (3, 36) rather than RECIST (which is the 
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basis for the IRC).  This reflects the separate evolution of response criteria 
specifically designed for patients with lymphoma, as described above. Second, 
the IRC recommend restaging with a confirmatory study no less than 4 weeks 
following the initial assessment for aggressive tumors such as melanoma.  In 
patients with lymphoma treated with a finite number of cycles of treatment, 
restaging is not typically recommended until 6-8 weeks following completion of 
therapy to minimize false positive results.  Third, confirmatory studies are not 
required in lymphoma, since a response that does not persist for > 8 weeks is not 
usually considered clinically meaningful. Fourth, the IRC require at least a 25% 
increase in the bi-dimensional WHO criteria for solid tumors of a single lesion for 
PD, whereas an increase in the size of a single node is sufficient for considering 
lymphoma progression under certain circumstances (3). Lastly, the IRC are 
based on assessing tumor masses, which are always abnormal.  By contrast, 
lymph nodes, which are normally present, may be normal in size despite 
involvement by lymphoma, or may be enlarged by benign processes (e.g. fibrous 
or inflammatory tissue).   
 
For all the reasons outlined above, a modification of the Lugano Classification (3, 
36), notably with regard to the definition of PD, is needed to facilitate the 
development and maximize the potential therapeutic benefit of new drugs with 
immunological mechanisms of action.  The Lymphoma Research Foundation, in 
partnership with the Cancer Research Institute, convened a workshop focusing 
on the development of response guidelines for lymphomas in the setting of 
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immunomodulatory agents, particularly checkpoint inhibitors.  The objectives of 
the meeting were to address the unique response patterns characteristic of this 
class of agents, and to recommend appropriate adaptations of current lymphoma 
response criteria.  Participants included investigators with experience in the 
clinical use of checkpoint inhibitors, as well as representatives from companies 
involved in the development of those agents and from the U.S. Food and Drug 
Administration.  Based on this discussion, we propose a provisional modification 
of the Lugano criteria adapted to immune-based therapy, the LYmphoma 
Response to Immunomodulatory Therapy Criteria (LYRIC).  This modification 
retains the core concepts of IRC summarized above, incorporating them into 
lymphoma-specific response criteria.  This is primarily accomplished through the 
introduction of a new response category termed “Indeterminate Response” (IR).  
We stress the following points at the outset, which are further discussed in 
subsequent sections: 
1. This modification is based mostly on the experience with checkpoint 
blockade therapy, but the framework could potentially be used for other 
immunomodulatory agents if they are associated with similar atypical 
response patterns. 
2. The modification is provisional, since we anticipate that future analyses 
and developments may change or altogether eliminate the IR category.  
There are not at present sufficient data to rigorously support the details of 
the choices made here, but such a framework is required to reduce 
ambiguity in current trials, and to enable the collection of accurate data in 
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a consistent way which eventually, can then be used to support or modify 
those choices and the incorporation of LYRIC into clinical trials. 
 
The “Indeterminate response” category  
The term IR does not make direct reference to the underlying mechanism, 
recognizing that a delayed response and an immune-mediated flare can both 
occur in the early treatment period and may be difficult to distinguish from 
progression by physical exam or imaging alone.  Moreover, the term provides the 
flexibility to allow patients to continue treatment past IR in some circumstances 
with a mandatory subsequent evaluation within 12 weeks to confirm or refute true 
PD.   
 
The following summarizes the provisional definition, nomenclature, suggested 
management, follow-up and use of the IR category. 
I. Definition 
A patient will be considered to have Indeterminate Response (IR) in one or more 
of the 3 following circumstances: 
 
1. Increase in overall tumor burden (as assessed by SPD) of ≥50% of up to 6 
measurable lesions in the first 12 weeks of therapy, without clinical 
deterioration (IR(1))(Figure 3). 
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This pattern may be seen as a consequence of either delayed response or early 
immune-mediated flare.  At least within the context of clinical trials, a biopsy is 
encouraged in this case since this may help to distinguish the two and, if positive, 
will confirm the impression of PD.  However, if negative for lymphoma, it will 
support the concept of pseudo-progression and contribute to our understanding 
of this phenomenon.  When such a biopsy is neither safe nor feasible, decisions 
must be based on a repeat scan 12 weeks after the initial determination of IR 
(see “Follow-up” below).   
 
It is recognized that “clinical deterioration” is subjective.  In some cases, the 
simple growth of a nodal or tumor mass could worsen the symptoms 
mechanically related to that mass, such as pain at the tumor site, compression of 
adjacent structures, etc.  Such an increase in symptoms that can be directly 
attributed to the size of the tumor mass may not be considered as clinical 
deterioration in this context.  However, in most cases patients should be 
experiencing clinical stability or improvement by investigator assessment in order 
to be considered as having IR, and in all cases the patient must be considered 
likely to tolerate continued treatment and not at risk of serious complications 
should further tumor growth occur. 
 
2. Appearance of new lesions; or growth of one or more existing lesion(s) 
 ≥50%; at any time during treatment; occurring in the context of lack of 
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 overall progression (<50% increase) of overall tumor burden, as measured 
 by SPD of up to 6 lesions at any time during the treatment (IR(2)(Figure 4).   
 
This phenomenon may occur early or late in the treatment course, and therefore, 
unlike #1 above, is not defined by its temporal relationship to treatment initiation.  
Both within and outside the context of clinical trials, a biopsy is strongly 
encouraged in such cases.  If the biopsy does not confirm the presence of viable 
tumor in the new or enlarging lesion(s), then the lesion(s) are not considered 
active disease and should not be used in subsequent SPD assessments. 
 
 3. Increase in FDG uptake of one or more lesion(s) without a concomitant 
 increase in lesion size or number (IR(3))(Figure 5) 
 
Increased immune activity at the site of tumor may manifest as an increase in 
FDG uptake.  Therefore, by itself changes in uptake should not trigger an 
assignment of PD with checkpoint inhibitors.  The magnitude of increase in 
uptake in an immune-mediated flare compared to that in true tumor progression 
is not yet known. It is important to investigate this finding, especially in 
conjunction with biopsies of the lesion in question.   
 
While awaiting a better characterization of this phenomenon, we propose that, 
under the modified response criteria, an increase in FDG avidity of one or more 
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lesions suggestive of lymphoma, without a concomitant increase in size of those 
lesions meeting PD criteria does not constitute PD.  
 
It is possible that, at a single time point a patient could fulfill criteria for both IR(1 
or 2) AND IR(3): for example, there could be a new FDG-avid lesion in the 
absence of overall progression (IR(2)), and, at the same time, increase in FDG 
uptake of a separate lesion (IR(3)).  In such cases, the designation of IR(1 or 2) 
should take priority (e.g., IR(2) in the above example). 
 
These 3 patterns of “indeterminate” response as defined above (i.e, IR(1), IR(2), 
IR(3)) may have very different mechanisms and clinical implications.  Therefore, 
it is critical that data are collected in a consistent manner so that these 3 possible 
atypical response types occurring within the context of checkpoint inhibitors can 
be distinguished.   
 
II. Follow-up of IR 
In patients categorized as having any of the above types of IR, it is mandatory to 
obtain a repeat imaging after an additional 12 weeks (or earlier if clinically 
indicated).  At that time, response should be re-evaluated and the patient should 
be considered to have true PD if the SPD of target lesion has increased further, 
with the considerations below: 
• In the case of IR(1), the comparison should be between the first IR(1) and 
the current SPD, with an increase of >10% constituting PD.  In addition, 
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there should be an increase of > 5mm (in either dimension) of at least one 
lesion for lesions <2 cm, and 10 mm for lesions > 2 cm, to be consistent 
with the Lugano classification (3)(Table 2).  The 10% threshold is empiric 
but designed to account for variability in measurement (37), especially 
when taken along with the minimum increase.   If the target SPD increase 
is <10%, the response would still be categorized as IR(1), and the patient 
could continue treatment until a subsequent scan shows either true PD 
(>10% increase from first IR(1) time point and an increase of > 5mm in 
either dimension of at least one lesion) or response (>50% decrease from 
baseline).  In this situation, it is reasonable to repeat imaging in 4-8 weeks 
of the original IR(1) timepoint to ensure absence of significant further 
increase.   
• In the case of IR(2), the new or growing lesion(s) (unless biopsy proven to 
be benign) should be added to the target lesion(s), up to a total of no more 
than 6 total lesions.  If the SPD of the newly defined set of target lesions 
has increased ≥ 50% from their nadir value (which may precede the IR 
time point), the patient should be considered to have PD. 
• In the case of IR(3), since inflammatory responses may result in an 
increase in the standardized uptake value of a lesion, the patient will not 
be considered to have PD unless there is evidence of PD by an increase 
in lesion size or the development of new lesions, as noted above. 
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Importantly, if a patient is assessed as having IR and then “true” PD at a 
subsequent time point (without an intervening objective response between IR 
and PD), the IR assessment should subsequently be corrected to PD for 
reporting purposes to the date of the prior designation of IR.  We recognize that 
these lesions may remain stable during the time of observation, but, even if this 
is the case, the initial designation of IR should be changed to PD. 
 
III. Use of the IR category 
We propose that the modified response criteria outlined here be incorporated as 
secondary endpoints in upcoming clinical trials of immunomodulatory therapy 
(especially trials involving checkpoint blockade).  Moreover, we propose that the 
protocols using such agents allow the use of treatment past conventional PD, in 
the case of IR, as outlined in “Management” and “Follow-up” above.  This will not 
only allow patients to continue what may be beneficial therapy, but will allow the 
generation of data that can then be analyzed to determine whether this strategy 
of treatment past IR does indeed confer a clinical benefit, in a way similar to what 
has been done in solid tumors. 
 
Conclusions 
Despite the recently revised response criteria for lymphoma (3), modifications in 
treatment that affect image interpretation demand continued revision of the 
response criteria in order to optimize drug development and patient management. 
Moreover, the question of how best to apply response criteria in an era 
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increasingly focused on targeted treatments with prolonged duration of therapy 
has yet to be resolved, as does the question of when best to assess response in 
an era of continuous treatments. 
 
Immune modulating active agents are now entering the clinic in lymphoma in 
increasing numbers, and are likely to provide a valuable addition to our 
therapeutic arsenal.  Given the growing utilization of these agents, optimizing 
response assessment will be critical in order to maximize potential therapeutic 
benefit.  We hope that the addition of the IR category to standard response 
assessment will allow investigators to better understand this phenomenon, gain 
insights to the biological bases of response and flare, allow patients to derive 
maximal possible benefit from these drugs, and further refine immune-related 
response criteria for their application in hematologic malignancies as our 
knowledge matures.  Once we enlarge our data set and understanding, and can 
accurately distinguish delayed responses and flares from PD, the provisional 
term IR should disappear as has the former complete remission unconfirmed 
(CRu), so as not to artificially influence response rates. 
 
While the foregoing focused primarily on checkpoint blocking agents, similar 
considerations could potentially apply to other immunotherapies such as bi-
specific antibodies, engineered T cells, and others.  In the future, novel imaging 
methods and quantitative methods to measure tumor burden may also prove 
helpful in response assessment. There is currently growing interest in the use of 
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next-generation sequencing techniques for detecting minimal residual disease 
(MRD) in a number of lymphoma subtypes and studies are evaluating the role of 
circulating tumor cell DNA for response assessment as well (38, 39). 
 
Ultimately, it will always be challenging to match our assessment tools to our 
treatments. This ongoing effort is critical to maximize the early detection of 
treatment failure while limiting the possibility of discarding a useful treatment too 
soon.  Only through the continuous pursuit of this goal can we succeed in 
optimizing patient outcome. 
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Table 1. Immune Response Criteria (IRC) for Solid Tumors 
The overall response according to the irRC is derived from time-point response 
assessments (based on tumor burden) as follows: 
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• irCR, complete disappearance of all lesions (whether measurable or not, 
and no new lesions), confirmed by a repeat, consecutive assessment no 
less than 4 weeks from the date first documented 
• irPR, decrease in tumor burden ≥50% relative to baseline confirmed by a 
consecutive assessment at least 4 weeks after first documentation 
• irSD, not meeting criteria for irCR or irPR, in absence of irPD 
• irPD, increase in tumor burden ≥25% relative to nadir (minimum recorded 
tumor burden),confirmed by a repeat, consecutive assessment no less 
sthan 4 weeks from the date first documented 
(Adapted from Wolchok et al (31)) 
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Table 2. Comparison of RECIST, irRC, and Lugano Classification Criteria 
 
Criteria CR PR PD 
RECIST 
1.1 
Disappearance of all 
target lesions. Any 
pathological lymph 
nodes (whether target or 
non-target) must have 
reduction in short axis to 
<10 mm 
At least a 30% 
decrease in the 
sum of diameters 
of target lesions, 
taking as reference 
the baseline sum 
diameters 
At least a 20% increase in 
the sum of diameters of 
target lesions, taking as 
reference the smallest sum 
on study (this includes the 
baseline sum if that is the 
smallest on study). In 
addition to the relative 
increase of 20%, the sum 
must also demonstrate an 
absolute increase of at least 
5 mm.  
Note: the appearance of one 
or more new lesions is also 
considered progression. 
irRC Disappearance of all 
lesions in two 
consecutive 
observations not less 
than 4 weeks apart 
≥50% decrease in 
tumor burden 
compared with 
baseline in two 
observations at 
> 25% increase in tumor 
burden compared with nadir 
(at any single time point) in 
two consecutive 
observations at least 4 
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least 4 weeks apart 
(as measured 
bidimensionally) 
weeks apart. Where Tumor 
Burden = SPD index lesions 
+ SPD new, measurable 
lesions 
Lugano PET-CT, score 1, 2, or 
3* with or without a 
residual mass on 5PS†  
OR  
on CT, target 
nodes/nodal masses 
must regress to ≤ 1.5 
cm in LDi 
 
PET-CT Score 4 or 
5 with reduced 
uptake compared 
with baseline and 
residual mass(es) 
of any size.   
OR 
On CT ≥ 50% 
decrease in SPD of 
up to 6 target 
measurable nodes 
and extranodal 
sites 
PET-CT score 4 or 5 with an 
increase in intensity of 
uptake from baseline and/or  
new FDG-avid foci 
consistent with lymphoma at 
interim or end-of-treatment 
assessment.  
OR 
On CT, an individual 
node/lesion must be 
abnormal with: 
LDi > 1.5 cm and 
Increase by ≥ 50% from PPD 
nadir and 
An increase in LDi or SDi 
from nadir 
0.5 cm for lesions ≤ 2 cm 
1.0 cm for lesions > 2 cm 
In the setting of 
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splenomegaly, the splenic 
length must increase by > 
50% of the extent of its prior 
increase beyond baseline 
(eg, a 15-cm spleen must 
increase to > 16 cm). If no 
prior splenomegaly, must 
increase by at least 2 cm 
from baseline 
New or recurrent 
splenomegaly. 
New or clear progression of 
preexisiting nonmeasured 
lesions.   
Regrowth of previously 
resolved lesions. 
A new node > 1.5 cm in any 
axis or a new extranodal site 
> 1.0 cm in any axis; if < 1.0 
cm in any axis, its presence 
must be unequivocal and 
must be attributable to 
lymphoma 
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Assessable disease of any 
size unequivocally 
attributable to lymphoma 
AND/OR  
New or recurrent 
involvement of the bone 
marrow 
LYRIC Same as Lugano Same as Lugano As with Lugano with the 
following exceptions: 
Indeterminate response (IR) 
IR1: >50% increase in SPD 
in first 12 wks 
IR2: <50% increase in SPD 
with 
   a. New lesion(s), or 
   b. >50% increase in PPD 
of a lesion or set of lesions 
at any time during treatment 
IR(3): Increase in FDG 
uptake without a 
concomitant increase in 
lesion size meeting criteria 
for PD 
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SPD – sum of the product of the diameters; PPD – product of the perpendicular 
diameters; LDi – longest diameter; SDi – short diameter; 5PS – 5 point scale; IR 
– immune response 
*A score of 3 in many patients indicates a good prognosis with standard 
treatment, especially if at the time of an interim scan. However, in trials involving 
PET where de-escalation is investigated, it may be preferable to consider a score 
of 3 as inadequate response (to avoid undertreatment).  
†PET 5PS: 1, no uptake above background; 2, uptake ≤ mediastinum; 3, uptake 
> mediastinum but ≤ liver; 4, uptake greater than liver; 5, uptake markedly higher 
than liver (2-3times SUVmax in normal liver) and/or new lesions; X, new areas of 
uptake unlikely to be related to lymphoma. 
 
 
Figure legends: 
Fig. 1. This case illustrates a discrepancy between the revised Lugano 
Classification (PD) and the immune-related response criteria (PR) given the fact 
that the immune-related response criteria do not take into consideration PET/CT 
findings. This type of discrepancy is particularly notable in cases with bone 
marrow involvement. Oftentimes, lymphomatous involvement of the bone marrow 
is either not measurable (due to absence of soft tissue component) or 
imperceptible on CT. Therefore, these findings cannot be integrated in the tumor 
burden of the immune-related response criteria. Restaging PET-CT is at 12 
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weeks Restaging PET/CT 2 at 20 weeks demonstrates new areas of FDG uptake 
in the left side of T9 vertebral body (arrows) and increasing uptake in the left 
acetabulum suggesting increasing extent of marrow disease, while this is barely 
seen on CT.  Marked physiological uptake is also seen in brown fat (asterisks). 
Figure 2. Restaging FDG-PET/CT and contrast enhanced CT at 19 weeks 
demonstrate interval resolution of FDG-uptake in a liver lesion. Restaging 
contrast-enhanced CT shows interval decrease in size of the hepatic lesion 
(arrow). Since the lesion did not disappear, this patient achieved a PR by 
immune-related response criteria, while the absence of FDG uptake on FDG-
PET/CT is a CR by the Lugano Classification. There was also a complete 
metabolic response in the mediastinum and right upper abdomen (asterisks).   
Figure 3. IR(1): Restaging CT 1 at 3 weeks demonstrates overall progression of 
tumor burden (SPD +124% from baseline) as evidenced interval increase in a 
right upper lobe lung mass (black arrow), left-sided pleural masses (asterisks), 
and left retrocrural lymphadenopathy (white arrow), and interval development of 
a large left-sided pleural effusion. Subsequent follow-up at 7 weeks (restaging 
CT 2) shows an interval decrease in size of all lesions with resolution of the left 
pleural effusion (SPD -27% from baseline). Additional follow-up at 13 weeks  
(restaging CT 3) demonstrates a further interval decrease in tumor burden and 
the patient achieved a PR by revised response criteria (SPD -54% from baseline) 
with clear subsequent clinical benefit from continued treatment.  
Figure 4. IR(2): CT demonstrating pseudo-progression in a patient on nivolumab 
for Hodgkin lymphoma.  May 2015, pre-treatment, October and December 2015 
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shows transient flares in different nodal groups without overall progression in the 
original target lesions. 
Figure 5. IR(3) showing an increase in FDG uptake in a paracardiac node 
suggestive of lymphoma without a concomitant increase in size of lesion(s) that 
meets PD criteria. 
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